Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Objectives:
Primary objective: Evaluate toxicity of rapamycin when used for post-bone marrow transplant
graft vs. host disease prophylaxis in children with acute lymphoblastic leukemia (ALL).
Investigator initiated; four participating institutions; Phase II pilot study